Quantcast
Last updated on April 18, 2014 at 12:32 EDT

Latest FOLFOX Stories

2010-01-07 07:00:00

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today provided an overview of its 2010 corporate, clinical and regulatory goals for picoplatin. "Our focus in 2010 is to secure a strategic partnership to continue the development of picoplatin as a preferred platinum agent in the treatment of solid tumor malignancies. We believe that current data from approximately 1,100 patients treated with picoplatin, including data from Phase 2...

2009-11-17 11:52:00

SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, has comparable efficacy to oxaliplatin, given in combination with 5-fluorouracil and...

2009-11-05 07:03:00

THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging...

2009-09-24 02:37:00

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard...

2009-05-28 07:01:00

- New Progression-Free Survival, Disease Control and Neurotoxicity Data To Be Presented at 2009 ASCO Annual Meeting Continue to Support Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for First-Line Treatment of Colorectal Cancer - - Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on...

2009-04-21 09:00:00

- Safety and Tumor Response Data from Dose-Escalation Study Presented at American Association for Cancer Research's 100th Annual Meeting 2009 - SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated that...

2009-01-14 07:00:00

- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment - SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with...

2009-01-13 17:00:00

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer. In the study, patients receiving XELOX...

2008-12-19 07:00:00

NEW YORK, Dec. 19 /PRNewswire/ -- Cancer advocacy organization Gilda's Club Worldwide offers a message of hope this holiday season to the millions touched by colon cancer with a one-of-a-kind mosaic mural at its New York City headquarters. The 15X6 foot mural was created by more than 165 colon cancer survivors from around the nation as part of a new MOSAIC of Colon Cancer Survivorship program celebrating the strides that have improved colon cancer treatment. According to the American...

2008-10-23 12:00:26

Poniard Pharmaceuticals, a biopharmaceutical company, has announced positive incremental data from its randomized, controlled Phase II clinical trial of picoplatin in patients with metastatic colorectal cancer. The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and...